Fiduciary Alliance LLC Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Fiduciary Alliance LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 11.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,107 shares of the company’s stock after purchasing an additional 829 shares during the period. Fiduciary Alliance LLC’s holdings in Novo Nordisk A/S were worth $697,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S in the second quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Abound Wealth Management increased its holdings in Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after acquiring an additional 157 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the third quarter worth about $42,000. Finally, Carolina Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $48,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $84.43 on Tuesday. The business’s 50-day moving average price is $99.84 and its 200 day moving average price is $118.61. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The company has a market capitalization of $378.88 billion, a PE ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on NVO. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.